Drug Profile

Research programme: metformin/atypical antipsychotic - BTG

Alternative Names: Metformin/atypical antipsychotic

Latest Information Update: 21 Aug 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BTG
Class Biguanides
Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 5-HT2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
16 Jul 2016 No recent reports of development identified for preclinical development in Obesity(Combination therapy) in United Kingdom (PO)
01 Jun 2007 Preclinical trials in Obesity in United Kingdom (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com